Drugs / [68Ga]Ga-NOTA-SNA002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05490264 | Oct 2022 → Jun 2024 | neoplasm | SmartNuclide Biopharma | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-NOTA-SNA002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490264 ↗ |
| Modality | Diagnostic / imaging agent | “PD-L1 PET Tracer” NCT05490264 ↗ |
| Route | Intravenous | “will be administered intravenously over 5minutes” NCT05490264 ↗ |